Schering-Plough files asthma combination in Europe
This article was originally published in Scrip
The European Medicines Agency (EMEA) has agreed to review Schering-Plough's centralised EU application for approval to market a fixed-dose inhaled combination of its corticosteroid Asmanex (mometasone furoate) and the long-acting beta-2 agonist formoterol fumarate (Novartis's Foradil) for the maintenance treatment of asthma in patients aged 12 years and older.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.